Status: Not yet recruiting
Study of NM8074 in Patients With aHUS With Evidence of Ongoing Thrombotic Microangiopathy
This is a Phase II, open-label study designed to determine if intravenously administered NM8074 results in remission from TMA in treatment-naïve aHUS patients.
Participants needed: 12
Trial details
Phase: Phase 2Age: 18-65Biological sex: AllType: InterventionalSponsor: NovelMed TherapeuticsUpdated: Apr 13, 2026
Eligibility criteria
Patients ≥ 18 years at the time of consent [+10]
History of bone marrow, hematopoietic stem cell, or solid organ transplantation [+14]